XML 37 R40.htm IDEA: XBRL DOCUMENT
v3.20.1

Collaborative Arrangements and Licensing Agreements, Biogen (Details) $ in Thousands | 3 Months Ended |
--- | --- | ---
Mar. 31, 2020 USD ($) Medicine | Mar. 31, 2019 USD ($) | Dec. 31, 2019 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Revenue | $ 133,367 | $ 297,214 |
SPINRAZA Royalties [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Revenue | 66,008 | 59,711 |
R&D Revenue [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Revenue | $ 49,406 | 229,126 |
Biogen [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Number of medicines currently being developed | Medicine | 8 |  |
Cumulative payments received | $ 2,500,000 |  |
Revenue | 87,400 | $ 84,200 |
Deferred revenue | $ 512,300 |  | $ 525,800
Biogen [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Concentration percentage | 66.00% | 28.00% |
Biogen [Member] | SPINRAZA Royalties [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Revenue | $ 66,000 | $ 59,700 |
Biogen [Member] | R&D Revenue [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Revenue | 21,400 | $ 24,500 |
2012 Neurology [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Milestone payment achieved | 7,500 |  |
Payments included in transaction price for performance obligation | 7,500 |  |
2012 Neurology [Member] | IONIS-MAPT [Member] |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |
Cumulative payments included in transaction price for performance obligation | $ 45,000 |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation. + References No definition available. + Details
Name: | ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment achieved during the period. + References No definition available. + Details
Name: | ions_MilestonePaymentAchieved
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of medicines currently being developed under the collaboration agreement(s). + References No definition available. + Details
Name: | ions_NumberOfMedicinesBeingDeveloped
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments received under the collaboration agreement during the period included in the transaction price for the performance obligation. + References No definition available. + Details
Name: | ions_PaymentsIncludedInTransactionPriceForPerformanceObligation
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_IONISMAPTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |